Roberta Lorenzon, Claire Ribet, Fabien Pitoiset, Selim Aractingi, Beatrice Banneville, Laurent Beaugerie, Francis Berenbaum, Patrice Cacoub, Julien Champey, Olivier Chazouilleres, Christophe Corpechot, Bruno Fautrel, Arsène Mekinian, Elodie Regnier, David Saadoun, Joe-Elie Salem, Jérémie Sellam, Philippe Seksik, Eric Vicaut, Michelle Rosenzwajg, David Klatzmann
BACKGROUND: A Tregs insufficiency is central to autoimmune and inflammatory diseases pathophysiology and low dose interleukin-2 (IL-2LD ) can specifically activate Tregs. OBJECTIVE: To assess IL-2LD therapeutic potential and select diseases for further clinical development, we performed an open-label, phase 2a, disease-finding, "basket trial" involving patients with one of 13 different autoimmune diseases. METHODS: 81 patients treated with IL-2LD (1 million IU/day) for 5 days, followed by fortnightly injections...
February 7, 2024: Journal of Autoimmunity